TCRX TScan Therapeutics, Inc.
Listings ·
TScan's board will set the reverse split ratio between one-for-two and one-for-fifty, and stockholders vote on November 20, 2026. Nasdaq's bid price deadline is February 23, 2027, and the stock closed at $0.2379 on October 12, 2026.
TScan will cut about 75% of its workforce, stop enrolling its phase 3 ALLOHA-2 trial for lack of capital and focus on solid tumors. Amgen is also ending a Crohn's disease collaboration, and Nasdaq has warned that the stock failed the $1.00 minimum bid for 30 straight trading days.
TScan expects annual cost savings of $45.0 million in 2026 and 2027 and a one-time charge of up to approximately $2.3 million. It says its cash runway now extends into the second half of 2027.
TScan sold pre-funded warrants for 7,500,000 voting shares at $4.00 each in a registered direct offering to Lynx1 entities, for about $30.0 million gross. It says cash will fund operations into the first quarter of 2027, on assumptions that may prove wrong.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $10.3 million | $2.8 million |
| Research and development | $114.2 million | $107.3 million |
| Net income (loss) | -$129.8 million | -$127.5 million |
| Cash from operations | -$135.3 million | -$110.8 million |
| Cash and equivalents | $152.4 million | $178.7 million |
| Short-term investments | $111.4 million |
Our latest story on this, dated Oct 26, 2026: "TScan Therapeutics asks stockholders to approve a reverse split of up to one-for-fifty". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Dec 26, 2024: "TScan Therapeutics agrees to sell $30.0 million of pre-funded warrants to Lynx1". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 2, 2026: "TScan cuts 75% of staff and pauses phase 3 trial for lack of capital". The story links the filing or release it is based on. Read the story.
TScan Therapeutics, Inc. trades under the ticker TCRX on NASDAQ.
TScan Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for TScan Therapeutics, Inc. is 1783328. Its filings are on SEC EDGAR.
23,976,942 shares as of 2022-03-04, per the cover page of its 10-K filed 2022-03-09.
Our directory records TScan Therapeutics, Inc. under United States.
Our directory classifies TScan Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for TScan Therapeutics, Inc. is US89854M1018.
aibio.space lists TScan Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$10.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
TScan Therapeutics, Inc. reported a net loss of $129.8 million for the fiscal year ended Dec 31, 2025, and used $135.3 million of cash in operations, per its annual report to the SEC.
$114.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.05,3.01,5.02,7.01,8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio